TRANSCOLONCAN will be organized in the following working groups:
Disease Risk Profiling (WG1)
Application of disease risk profiling for the optimization of current screening programs.
Use of germline predisposition variants, environmental factors, epigenetics, microbiome and metabolomics biomarkers to better select patients eligible to be screened.
WG1 Leaders: Claire Palles, Toni Gabaldon, Barbara Pardini, Victor Moreno, David Kerr (Oxford Cancer Biomarkers)
Non-invasive Biomarkers (WG2)
Development of non-invasive biomarkers for early detection and disease follow-up.
Exploration of circulating tumor cells, circulating tumor nucleic acids, tumor-educated platelets and exosomes in order to identify new tools for early detection and monitoring of the disease.
WG2 Leaders: Veronika Vymetalkova, Nikolas Stoecklein, Claus Lindberg Andersen, Michael Bretthauer, Alper Poyraz (PRZ Biotech)
Tumor Profiling (WG3)
Identification of biomarkers with prognostic and predictive value for patient stratification by tumor profiling.
Use of tumor mutational profiling, epigenetics and single-cell genomics sequencing, with consideration of intratumor heterogeneity, as instruments for better tumor and precursor lesion characterization.
WG3 Leaders: Jordi Camps, Romina Briffa, Beatriz Carvalho, Andreas Scorilas, Bart Janssen (GenomeScan)
Functional Genomics and Therapies (WG4)
Application of functional genomics and development of new therapies.
Validation of candidate genetic variants and conceiving of routes to novel therapies for the disease relying on cutting-edge approaches such as CRISPR-Cas9 and immunotherapy.
WG4 Leaders: Regine Schneider-Stock, Noel de Miranda, Laura Valle, Sreeparna Banerjee, Fabienne Hermitte (HalioDx)